Research Report Patient Access to Facility-Based Opioid Use Disorder Treatment in New Jersey in 2019
Lisa Clemans-Cope, Emma Winiski, Marni Epstein
Display Date
Download Report
(1.74 MB)

Expanding access to effective treatment for opioid use disorder (OUD) is essential to staunching the opioid epidemic. This brief presents findings from the second round of a telephone survey that assessed patient access to treatment services for OUD at facilities that offered OUD pharmacotherapy (buprenorphine, methadone, or naltrexone) across New Jersey in 2019. We also monitor changes in access to treatment from 2018 to 2019. We present data on specific treatment service availability, wait times, and Medicaid coverage of treatment, including region- and county-specific data to assess the supply and demand of various treatment options throughout the state. We find the following:

  • Fifty-six percent of substance use treatment facilities offered any form of OUD pharmacotherapy in 2019, up from 49 percent in 2018. 
  • Treatment facilities offering OUD pharmacotherapy remained concentrated in Northern New Jersey. 
  • Patients faced a median wait time of two days across all counties and services, though wait times varied widely across both county and service type.
Research Areas Health and health care
Tags Health care delivery and payment Health equity Maternal, child, and reproductive health Substance use Opioid crisis
Policy Centers Health Policy Center
Related content